Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG MIX 75 25 PEN versus NOVOLOG MIX 70 30 PENFILL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG MIX 75 25 PEN versus NOVOLOG MIX 70 30 PENFILL.
HUMALOG MIX 75/25 PEN vs NOVOLOG MIX 70/30 PENFILL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin analog with intermediate-acting insulin (insulin lispro protamine suspension) and rapid-acting insulin (insulin lispro). Binds to insulin receptors, activating glucose uptake, glycogen synthesis, and lipogenesis, while inhibiting gluconeogenesis and ketogenesis.
Novolog Mix 70/30 is a biphasic insulin analog suspension containing 70% insulin aspart protamine (intermediate-acting) and 30% insulin aspart (rapid-acting). Insulin aspart binds to the insulin receptor (IR) on target cells (muscle, adipose, liver), activating tyrosine kinase signaling, which promotes glucose uptake via GLUT4 translocation, inhibits hepatic gluconeogenesis, and stimulates glycogen synthesis and lipogenesis.
Subcutaneous injection. Individualized based on metabolic needs. Typical total daily insulin dose: 0.5-1 unit/kg/day divided, with Humalog Mix 75/25 given 15 minutes before meals. Starting dose: 0.2-0.3 unit/kg/day for type 1 diabetes; 0.3-0.5 unit/kg/day for type 2 diabetes. Administer twice daily: before breakfast and before dinner. Dose adjustments based on blood glucose monitoring.
Subcutaneous injection, typically 0.5–1 unit/kg/day divided into two doses: two-thirds in the morning and one-third in the evening, adjusted based on blood glucose levels.
None Documented
None Documented
Insulin lispro protamine: 13-16 hours (intermediate component); Insulin lispro: 1-2 hours (rapid component). Clinical context: Steady state achieved after 2-4 days of dosing.
Biphasic: first phase (distribution) 0.5-1 h; terminal (elimination) 5-7 h (insulin aspart component). Clinical context: covers prandial and basal needs with twice-daily dosing.
Renal: 30-80% (protamine-insulin complex clearance); Hepatic: 10-20% (degradation by insulinase); Fecal: <1%
Renal: 100% (protamine and insulin are metabolized and excreted via kidneys; no unchanged drug excreted in urine). Biliary/fecal: negligible.
Category C
Category C
Insulin Analog
Insulin Analog